ATHERTON, Calif.–(BUSINESS WIRE)–TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board
Uncategorized
National Vision Holdings, Inc. Details Transformation Strategy and Long-Term Financial Objectives Underpinning Bold Reinvention
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) will host an Investor Day at NASDAQ MarketSite in New York City today to detail its comprehensive transformation strategy and financial outl…
Uncategorized
Q&A: New milestone in osteopathic medicine shows profession is ‘hitting its stride’
The osteopathic medicine profession passed 200,000 physicians and medical students for the first time in the field’s over 150-year history, the American Osteopathic Association announced.The milestone “is a powerful testament to the growing trust patie…
Uncategorized
Real-world data show extended injection intervals with Eylea HD
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, discusses the real-world use of aflibercept 8 mg in wet age-related macular degeneration or diabetic macular edema.A study of data from the IRIS Registry looke…
Uncategorized
‘Meaningful improvement in vision’ seen in ELARA study
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Diana V. Do, MD, said aflibercept 8 mg showed vision improvement and a reduction in retinal thickness.The ELARA study evaluated frequent dosing of Eylea HD (aflibercept 8 mg, R…
Uncategorized
MCO-010 targets severe Stargardt disease in STARLIGHT study
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Kenneth C. Fan, MD, MBA, highlights outcomes of the STARLIGHT study in Stargardt disease.The 48-week open-label phase 2 clinical trial looked at the use of MCO-010 (Nanoscope T…